Bizhar Ahmed Tayeb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bizhar Ahmed Tayeb has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Renáta Minorics
Institute of Pharmacodynamics and Biopharmacy, University of Szeged, H-6720 Szeged, Hungary
6 shared publications - István Zupkó
Institute of Pharmacodynamics and Biopharmacy, University of Szeged, Eötvös u. 6., H-6720 Szeged, Hungary
4 shared publications - Antal Csámpai
Department of Organic Chemistry, Eötvös Loránd University (ELTE), Pázmány P. sétány 1/A, H-1117 Budapest, Hungary
2 shared publications - Attila Hunyadi
Institute of Pharmacognosy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary
2 shared publications - Dávid Papp
MTA-ELTE Lendület (Momentum) Ion Mobility Mass Spectrometry Research Group and Department of Analytical Chemistry, Institute of Chemistry, ELTE Eötvös Loránd University, Pázmány Péter sétány 1/A, H-1117 Budapest, Hungary
2 shared publications - Etelka Ferenczi
Department of Organic Chemistry, Eötvös Loránd University (ELTE), Pázmány P. sétány 1/A, H-1117 Budapest, Hungary
2 shared publications
Latest Publications
- 22 April 2026
- Published by Taylor & Francis in Infectious Diseases
- Vol. 58 (6) , 571-584
Therapeutic intervention strategies for Nipah virus infection: a scoping review
Nipah virus (NiV) infection, a zoonotic disease, has caused recurrent outbreaks in South and Southeast Asia, with case fatality rates ranging from 38% to 75%. The clinical management of NiV disease (NiVD) relies on supportive care, with unapproved antiviral therapies and no licensed vaccines currently available. This scoping review aims to synthesise and map the available evidence on therapeutic strategies for NiV infection. A systematic search was conducted in PubMed and Scopus for studies published from 1 January 1999 to 1 February 2026, focusing on clinical studies, animal experiments, in vitro investigations and in silico analyses evaluating NiV therapies. Eligible studies were selected based on their population or experimental model, therapeutic intervention, evaluation methods, efficacy outcomes, safety findings and proposed molecular mechanisms. Of 1703 articles screened, 16 studies were included, covering clinical reports, animal models, in vitro experiments and in silico analyses. Therapeutic interventions evaluated included antivirals (ribavirin, favipiravir, remdesivir and RdRp-targeted candidates), passive immunotherapy (monoclonal antibodies targeting viral glycoproteins) and computationally prioritised compounds (e.g. phytochemicals, bioisosteres and repurposed drugs). Most interventions targeted viral entry, RNA replication or multiple stages of the NiV life cycle. However, a substantial gap exists between the urgent clinical need for effective treatments and the limited availability of clinically validated therapies. Effective, clinically validated therapies for NiV infection are still lacking. Translational research, outbreak-ready clinical trial frameworks and prioritisation of promising therapeutic candidates are crucial for improving preparedness and clinical outcomes in future NiV outbreaks.
- 22 April 2026
- Published by Taylor & Francis in Infectious Diseases
- Vol. 58 (6) , 571-584
Therapeutic intervention strategies for Nipah virus infection: a scoping review
Nipah virus (NiV) infection, a zoonotic disease, has caused recurrent outbreaks in South and Southeast Asia, with case fatality rates ranging from 38% to 75%. The clinical management of NiV disease (NiVD) relies on supportive care, with unapproved antiviral therapies and no licensed vaccines currently available. This scoping review aims to synthesise and map the available evidence on therapeutic strategies for NiV infection. A systematic search was conducted in PubMed and Scopus for studies published from 1 January 1999 to 1 February 2026, focusing on clinical studies, animal experiments, in vitro investigations and in silico analyses evaluating NiV therapies. Eligible studies were selected based on their population or experimental model, therapeutic intervention, evaluation methods, efficacy outcomes, safety findings and proposed molecular mechanisms. Of 1703 articles screened, 16 studies were included, covering clinical reports, animal models, in vitro experiments and in silico analyses. Therapeutic interventions evaluated included antivirals (ribavirin, favipiravir, remdesivir and RdRp-targeted candidates), passive immunotherapy (monoclonal antibodies targeting viral glycoproteins) and computationally prioritised compounds (e.g. phytochemicals, bioisosteres and repurposed drugs). Most interventions targeted viral entry, RNA replication or multiple stages of the NiV life cycle. However, a substantial gap exists between the urgent clinical need for effective treatments and the limited availability of clinically validated therapies. Effective, clinically validated therapies for NiV infection are still lacking. Translational research, outbreak-ready clinical trial frameworks and prioritisation of promising therapeutic candidates are crucial for improving preparedness and clinical outcomes in future NiV outbreaks.
- Open Access
- 25 September 2025
- Published by Elsevier in The Journal of Liquid Biopsy
- Vol. 10, 100328
Liquid biopsy biomarkers in cervical cancer: A systematic review and meta-analysis
- 25 September 2025
- Published by Elsevier in The Journal of Liquid Biopsy
- Vol. 10, 100328
Open AccessLiquid biopsy biomarkers in cervical cancer: A systematic review and meta-analysis
- Open Access
- 4 June 2025
- Published by Iraqi Center for Cancer and Medical Genetics Research in Iraqi Journal of Cancer and Medical Genetics
- Vol. 18 (1) , 30-39
Exploring Dietary Patterns and Breast Cancer Risk: Epidemiological Insight from Sulaymaniyah City, Iraq
Objective: An increasing number of women are being diagnosed with breast cancer, which ranks as one of the most common cancers in women globally, particularly in developed nations. Although genetic environmental factors and lifestyle choices are all contributors to breast cancer risk, dietary habits are known to play a modifiable role in both the disease›s prevalence and prognosis; therefore, the aim of this study was to correlate dietary habits with the prevalence of breast cancer in Sulaymaniyah city, Iraq.Methods: Hiwa Oncological Hospital in Iraq›s Sulaymaniyah City was the site of the research. In all, 301 individuals who received a breast cancer diagnosis between June 2023 and January 2024 were included in the sample size. Patient demographics, medical history, eating habits, and other crucial details related to daily dietary regimens were among the data obtained. Once collected, the data were processed via IBM SPSS Statistics.Results: Among 301 breast cancer patients, 43.5% were aged 40--49 years, and 85.6% were married. Invasive ductal carcinoma (IDC) is the most prevalent subtype. Most patients (82.7%) followed a balanced diet, with IDC being the predominant subtype (73.9%). The majority (63.5%) consumed fruits and vegetables 1–2 times daily, while only 1% exceeded five servings. Additionally, 58.1% had no dietary restrictions, whereas 29.6% avoided sugar, meat, or fatty foods. It was observed that patients with uncontrolled dietary habits and lower fruit and vegetable intake were more likely to develop invasive breast cancer subtypes.Conclusion: These results emphasize the necessity of advocating for healthier lifestyles through nutritional habits and screening in order to decrease the increasing breast cancer burden in the region. In order to lower the incidence of breast cancer and improve outcomes, it may be essential to implement dietary interventions and early screening techniques within the population.
- 4 June 2025
- Published by Iraqi Center for Cancer and Medical Genetics Research in Iraqi Journal of Cancer and Medical Genetics
- Vol. 18 (1) , 30-39
Open AccessExploring Dietary Patterns and Breast Cancer Risk: Epidemiological Insight from Sulaymaniyah City, Iraq
Objective: An increasing number of women are being diagnosed with breast cancer, which ranks as one of the most common cancers in women globally, particularly in developed nations. Although genetic environmental factors and lifestyle choices are all contributors to breast cancer risk, dietary habits are known to play a modifiable role in both the disease›s prevalence and prognosis; therefore, the aim of this study was to correlate dietary habits with the prevalence of breast cancer in Sulaymaniyah city, Iraq.Methods: Hiwa Oncological Hospital in Iraq›s Sulaymaniyah City was the site of the research. In all, 301 individuals who received a breast cancer diagnosis between June 2023 and January 2024 were included in the sample size. Patient demographics, medical history, eating habits, and other crucial details related to daily dietary regimens were among the data obtained. Once collected, the data were processed via IBM SPSS Statistics.Results: Among 301 breast cancer patients, 43.5% were aged 40--49 years, and 85.6% were married. Invasive ductal carcinoma (IDC) is the most prevalent subtype. Most patients (82.7%) followed a balanced diet, with IDC being the predominant subtype (73.9%). The majority (63.5%) consumed fruits and vegetables 1–2 times daily, while only 1% exceeded five servings. Additionally, 58.1% had no dietary restrictions, whereas 29.6% avoided sugar, meat, or fatty foods. It was observed that patients with uncontrolled dietary habits and lower fruit and vegetable intake were more likely to develop invasive breast cancer subtypes.Conclusion: These results emphasize the necessity of advocating for healthier lifestyles through nutritional habits and screening in order to decrease the increasing breast cancer burden in the region. In order to lower the incidence of breast cancer and improve outcomes, it may be essential to implement dietary interventions and early screening techniques within the population.
- Open Access
- 6 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (13) , 7428
Synthesis and Antiproliferative Effect of New Alkyne-Tethered Vindoline Hybrids Containing Pharmacophoric Fragments
In the frame of our diversity-oriented research on multitarget small molecule anticancer agents, utilizing convergent synthetic sequences terminated by Sonogashira coupling reactions, a preliminary selection of representative alkyne-tethered vindoline hybrids was synthesized. The novel hybrids with additional pharmacophoric fragments of well-documented anticancer agents, including FDA-approved tyrosine-kinase inhibitors (imatinib and erlotinib) or ferrocene or chalcone units, were evaluated for their antiproliferative activity on malignant cell lines MDA-MB-231 (triple negative breast cancer), A2780 (ovarian cancer), HeLa (human cervical cancer), and SH-SY5Y (neuroblastoma) as well as on human embryonal lung fibroblast cell line MRC-5, which served as a reference non-malignant cell line for the assessment of the therapeutic window of the tested hybrids. The biological assays identified a trimethoxyphenyl-containing chalcone-vindoline hybrid (36) as a promising lead compound exhibiting submicromolar activity on A2780 cells with a marked therapeutic window.
- 6 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (13) , 7428
Open AccessSynthesis and Antiproliferative Effect of New Alkyne-Tethered Vindoline Hybrids Containing Pharmacophoric Fragments
In the frame of our diversity-oriented research on multitarget small molecule anticancer agents, utilizing convergent synthetic sequences terminated by Sonogashira coupling reactions, a preliminary selection of representative alkyne-tethered vindoline hybrids was synthesized. The novel hybrids with additional pharmacophoric fragments of well-documented anticancer agents, including FDA-approved tyrosine-kinase inhibitors (imatinib and erlotinib) or ferrocene or chalcone units, were evaluated for their antiproliferative activity on malignant cell lines MDA-MB-231 (triple negative breast cancer), A2780 (ovarian cancer), HeLa (human cervical cancer), and SH-SY5Y (neuroblastoma) as well as on human embryonal lung fibroblast cell line MRC-5, which served as a reference non-malignant cell line for the assessment of the therapeutic window of the tested hybrids. The biological assays identified a trimethoxyphenyl-containing chalcone-vindoline hybrid (36) as a promising lead compound exhibiting submicromolar activity on A2780 cells with a marked therapeutic window.
- Open Access
- 31 May 2024
- Published by MDPI AG in Preprints.org
Synthesis and Antiproliferative Effect of New Alkyne-Tethered Vindoline Hybrids Containing Pharmacophoric Fragments
In the frame of our diversity-oriented research on multitarget small molecule anticancer agents, utilizing convergent synthetic sequences terminated by Sonogashira coupling reactions, a preliminary selection of representative alkyne-tethered vindoline hybrids was synthesized. The novel hybrids with additional pharmacophoric fragments of well-documented anticancer agents, including FDA-approved tyrosine-kinase inhibitors (imatinib and erlotinib) or ferrocene or chalcone units, were evaluated for their antiproliferative activity on malignant cell lines MDA-MB-231 (triple negative breast cancer), A2780 (ovarian cancer), HeLa (human cervical cancer) and SH-SY5Y (neuroblastoma) as well as human embryonal lung fibroblast MRC-5 served as reference non-malignant cell line for the assessment of the therapeutic window of the tested hybrids. The biological assays identified a trimethoxyphenyl-containing chalcone-vindoline hybrid (36) as a promising lead compound exhibiting submicromolar activity on A2780 cells with a marked therapeutic window. These results suggest that ovarian cancer might be considered as a prioritized target of treatment with 36.
- 31 May 2024
- Published by MDPI AG in Preprints.org
Open AccessSynthesis and Antiproliferative Effect of New Alkyne-Tethered Vindoline Hybrids Containing Pharmacophoric Fragments
In the frame of our diversity-oriented research on multitarget small molecule anticancer agents, utilizing convergent synthetic sequences terminated by Sonogashira coupling reactions, a preliminary selection of representative alkyne-tethered vindoline hybrids was synthesized. The novel hybrids with additional pharmacophoric fragments of well-documented anticancer agents, including FDA-approved tyrosine-kinase inhibitors (imatinib and erlotinib) or ferrocene or chalcone units, were evaluated for their antiproliferative activity on malignant cell lines MDA-MB-231 (triple negative breast cancer), A2780 (ovarian cancer), HeLa (human cervical cancer) and SH-SY5Y (neuroblastoma) as well as human embryonal lung fibroblast MRC-5 served as reference non-malignant cell line for the assessment of the therapeutic window of the tested hybrids. The biological assays identified a trimethoxyphenyl-containing chalcone-vindoline hybrid (36) as a promising lead compound exhibiting submicromolar activity on A2780 cells with a marked therapeutic window. These results suggest that ovarian cancer might be considered as a prioritized target of treatment with 36.
- Open Access
- 29 March 2024
- Published by Wiley in Neuroprotection
- Vol. 2 (2) , 151-166
Beyond boundaries: Neuroprotective effects of steroids and ecdysteroids in SH‐SY5Y cells ‐ A systematic review
Steroids and ecdysteroids have been shown to exhibit a range of biological effects, including anti‐inflammatory, anticancer, and neuroprotective. This systematic review aims to highlight the evidence‐based neuroprotective and antioxidant effects of steroids and ecdysteroids in SH‐SY5Y neuroblastoma cells. A comprehensive literature search was conducted on May 11, 2023, without publication source restrictions, using various electronic databases, including PubMed, Web of Science (WoS), Scopus, and Cumulative Index to Nursing and Allied Health Literature. Of 103 articles, only 20 studies were included for investigating the neuroprotective effects of steroids and ecdysteroids in SH‐SY5Y cells exposed to oxidative stress or neurotoxic agents. The risk of bias and quality assessment of the included studies were evaluated in accordance with the Nature Publication Quality Improvement Project specific criteria. The selected studies reported the antioxidant effects of the tested compounds on SH‐SY5Y cells and demonstrated their ability to scavenge free radicals and prevent lipid peroxidation. These findings suggest that neurosteroids have potential therapeutic applications for the prevention and treatment of neurodegenerative diseases characterized by oxidative stress and neuronal damage. Some studies have investigated the molecular mechanisms underlying the neuroprotective and antioxidant effects of steroids and ecdysteroids in SH‐SY5Y cells. These mechanisms include the activation of antioxidant enzymes, such as superoxide dismutase and glutathione peroxidase, and the modulation of various signaling pathways, including the phosphoinositide 3‐kinase/protein kinase B and mitogen‐activated protein kinase/extracellular signal‐regulated kinase pathways. This review provides evidence that the tested compounds have remarkable neuroprotective and antioxidant effects in human neuroblastoma SH‐SY5Y cells.
- 29 March 2024
- Published by Wiley in Neuroprotection
- Vol. 2 (2) , 151-166
Open AccessBeyond boundaries: Neuroprotective effects of steroids and ecdysteroids in SH‐SY5Y cells ‐ A systematic review
Steroids and ecdysteroids have been shown to exhibit a range of biological effects, including anti‐inflammatory, anticancer, and neuroprotective. This systematic review aims to highlight the evidence‐based neuroprotective and antioxidant effects of steroids and ecdysteroids in SH‐SY5Y neuroblastoma cells. A comprehensive literature search was conducted on May 11, 2023, without publication source restrictions, using various electronic databases, including PubMed, Web of Science (WoS), Scopus, and Cumulative Index to Nursing and Allied Health Literature. Of 103 articles, only 20 studies were included for investigating the neuroprotective effects of steroids and ecdysteroids in SH‐SY5Y cells exposed to oxidative stress or neurotoxic agents. The risk of bias and quality assessment of the included studies were evaluated in accordance with the Nature Publication Quality Improvement Project specific criteria. The selected studies reported the antioxidant effects of the tested compounds on SH‐SY5Y cells and demonstrated their ability to scavenge free radicals and prevent lipid peroxidation. These findings suggest that neurosteroids have potential therapeutic applications for the prevention and treatment of neurodegenerative diseases characterized by oxidative stress and neuronal damage. Some studies have investigated the molecular mechanisms underlying the neuroprotective and antioxidant effects of steroids and ecdysteroids in SH‐SY5Y cells. These mechanisms include the activation of antioxidant enzymes, such as superoxide dismutase and glutathione peroxidase, and the modulation of various signaling pathways, including the phosphoinositide 3‐kinase/protein kinase B and mitogen‐activated protein kinase/extracellular signal‐regulated kinase pathways. This review provides evidence that the tested compounds have remarkable neuroprotective and antioxidant effects in human neuroblastoma SH‐SY5Y cells.
- 28 February 2024
- Published by Elsevier in Journal of Integrative Medicine
- Vol. 22 (2) , 137-162
Herbal compounds as promising therapeutic agents in precision medicine strategies for cancer: A systematic review
- 28 February 2024
- Published by Elsevier in Journal of Integrative Medicine
- Vol. 22 (2) , 137-162
Herbal compounds as promising therapeutic agents in precision medicine strategies for cancer: A systematic review
- Open Access
Thymoquinone-Protoflavone Hybrid Molecules as Potential Antitumor Agents
We describe herein the synthesis of eight new ester-coupled hybrid compounds from thymoquinone and protoflavone building blocks, and their bioactivity testing against multiple cancer cell lines. Among the hybrids, compound 14 showed promising activities in all cell lines studied. The highest activities were recorded against breast cancer cell lines with higher selectivity to MDA-MB-231 as compared to MCF-7. Even though the hybrids were found to be completely hydrolysed in 24 h under cell culture conditions, compound 14 demonstrated a ca. three times stronger activity against U-87 glioblastoma cells than a 1:1 mixture of its fragments. Protoflavone-thymoquinone hybrids may therefore serve as potential new antitumor leads particularly against glioblastoma.
Open AccessThymoquinone-Protoflavone Hybrid Molecules as Potential Antitumor Agents
We describe herein the synthesis of eight new ester-coupled hybrid compounds from thymoquinone and protoflavone building blocks, and their bioactivity testing against multiple cancer cell lines. Among the hybrids, compound 14 showed promising activities in all cell lines studied. The highest activities were recorded against breast cancer cell lines with higher selectivity to MDA-MB-231 as compared to MCF-7. Even though the hybrids were found to be completely hydrolysed in 24 h under cell culture conditions, compound 14 demonstrated a ca. three times stronger activity against U-87 glioblastoma cells than a 1:1 mixture of its fragments. Protoflavone-thymoquinone hybrids may therefore serve as potential new antitumor leads particularly against glioblastoma.